BAX gene mutations occur in approximately 50% of RER+ colorectal cancers. To determine the role of these mutations in tumour progression we analysed multiple dierent tumour sites from RER+ colorectal cancers for BAX mutations. Sixty colorectal carcinomas were analysed for microsatellite instability at loci BAT-26, L-myc, TGFbRII, D13S160 and D2S123. Twelve out of 60 tumours (20%) were RER+. Forty-®ve dierent tumour sites from the 12 RER+ carcinomas were analysed for BAX mutations at the [(G)8] tract in exon 3. Six out of 12 (50%) RER+ tumours showed BAX mutations, four of which showed a homogenous pattern of such mutations detected in all tumour sites. In the other two cases, BAX mutations were present in some but not all tumour sites sampled from the same patient. In contrast, TGFbRII mutations were found in 9/12 cases (75%) and in each of these were present in all the sampled sites. Two cases showed neither BAX nor TGFbRII mutation. These data suggest that mutations in TGFbRII may occur at a very early stage in tumour progression, perhaps in the founder clone. BAX mutations, however, are clearly not necessary for formation of the founder clone and can occur for the ®rst time later in tumour progression.
Introduction
The BCL2 family of proteins control an important checkpoint prior to activation of the caspase family of proteases in apoptosis (Brown, 1997; White, 1996) . One prominent, widely expressed member of this family is BAX, a 21 kDa protein with the capacity to homodimerize or heterodimerize with other members of the BCL2 family (Oltvai et al., 1993) . Whereas BAX-BAX homodimers are potent death inducers, the BAX-BCL2 heterodimers and BCL2-BCL2 homodimers appear to promote survival (Kroemer, 1997) . Moreover, the tumour suppressor protein p53, a major element in the response to lethal stimuli arising from DNA damage or hypoxia, can transactivate BAX (Miyashita and Reed, 1995) whilst down-regulating BCL2 (Miyashita et al., 1994) . BAX is thus a signi®cant eector in the initiation of apoptosis.
Recently, clonally expanded, inactivating mutations in BAX have been observed in a proportion of colorectal cancers, together with evidence for underexpression of the BAX protein in these tumours (Rampino et al., 1997; Yamamoto et al., 1998; Yagi et al., 1998; Ouyang et al., 1998) . This provides some circumstantial evidence for the hypothesis that the founder cells of cancers may arise through selective loss of a death pathway and the resultant inappropriate survival of cells that have sustained DNA damage or other severe intracellular injury. This hypothesis carries the signi®cant implication that cancer cells that arise in this way are liable to be resistant to many cytotoxic agents to which more normal cells would be sensitive, because of constitutional loss of a critical death pathway. Alternative explanations for the BAX mutations exist, however. These mutations are restricted to tumours with mismatch repair (MMR) de®ciency, and usually occur in a tract of eight consecutive deoxyguanosines [(G)8] in the third coding exon (Rampino et al., 1997) . Since this is a classical target site for nucleotide mismatch (Aaltonen et al., 1993; Thibodeau et al., 1993) , it is possible that mutations within [(G)8] simply re¯ect the wellrecognized eect of MMR de®ciency on mutation incidence in tandem repeat microsatellite sequences.
In this paper we seek to distinguish between these possibilities by studying the homogeneity of BAX mutation within colorectal cancers. We argued that genetic changes that are critical for carcinogenesis are likely to be shared by all cells in the expanding tumour and should therefore be detectable at all sites throughout the tumour. In contrast, changes that re¯ect the genomic instability of malignant cells, but are not essential for the transition to malignancy might be expected to occur in some but not all of the divergent subclones within the given tumour. Accordingly, in this paper we studied BAX mutations in the [(G)8] tract in a series of tumours sampled at multiple sites.
Results

RER characterization
Twelve out of 60 patients (20%) demonstrated microsatellite instability (Table 1 ). In some cases (nos. 17, 27, 52, 53 and 55) individual tumour sites from the same carcinoma demonstrated dierent sets of mutations at the ®ve microsatellite loci tested. In some tumours, biopsies from dierent sites each exhibited dierent mutations at the same microsatellite locus (Figure 1 ). However, in no case was microsatellite instability present at one tumour site, and completely absent at all tested loci in others. Hence it was possible to classify all sampled sites of all tumours as RER+, although in two tumours (nos. 18 and 22) the instability was evident in only one of the ®ve tested loci.
BAX mutation analysis
Mutation in the BAX [(G)8] mononucleotide repeat tract occurred in six out of 12 (50%) RER+ tumours. In ®ve, this involved loss of a repeated nucleotide and in one a gain. Four showed a homogenous pattern, with identical changes in [(G)8] detected in all sites sampled from each carcinoma ( Figure 2a and Table 1 ). In the other two cases, however, [(G)8] BAX mutations were present in some but absent in other sites from the same cancers. Thus, case number 17 showed mutation in tumour sites A and B, but not C and case number 25 showed mutations in A, B and D but not C ( Figure  2b and Table 1 ). In both these cases, the tumour site in which BAX [(G)8] was unchanged showed unequivocal evidence of instability at most of the other tested microsatellite loci.
Discussion
It is clear that de®ciency in mismatch repair permits the generation of large numbers of mutations throughout the genome, mainly in microsatellite loci and repetitive polynucleotide tracts (Aaltonen et al., 1993; Thibodeau et al., 1993) . In sporadic colorectal tumours, the microsatellite instability is generally found in carcinomas but not adenomas, whereas both adenomas and carcinomas from HNPCC patients may show a high proportion of such instability (Samowitz and Slattery, 1997; Bubb et al., 1996; Jacoby et al., 1995; Thibodeau et al., 1993) . These observations strongly suggest that microsatellite instability is acquired at the adenoma-carcinoma interface in the evolution of sporadic tumours, but can appear at an (Chung et al., 1997) , as observed in the present work also. This indicates that a proportion of these microsatellite mutations are acquired as clonal variants throughout the process of tumour formation and re¯ect but do not cause the evolution of such tumours. In contrast, mutations at some genetic loci have been found with great consistency in RER+ tumours. An outstanding example is transforming growth factor beta-type 2 receptor (TGFbRII), which is mutated in upwards of 90% of all tested RER+ colorectal cancers . In this series, more than 75% of RER+ cancers showed a mutation in the one site within the TGFbRII gene which we tested. Together with independent evidence that TGFb exerts a suppressive eect on colorectal epithelial growth (Wrana et al., 1994) , these observations have been interpreted as indicative of a causal role for TGFbRII inactivation in colorectal carcinogenesis.
Frameshift mutations have been detected in the [(G)8] tract of exon 3 of the BAX gene in 48% of 63 RER+ sporadic colorectal cancers in a total of two separate studies (Rampino et al., 1997; Ouyang et al., 1998) , and in a similar proportion of RER+ colorectal cancers from HNPCC patients (Yamamoto et al., 1998; Yagi et al., 1998) . Our own observations are entirely concordant with these results: we detected BAX mutations in six out of 12 (50%) RER+ carcinomas. In the presence of BAX and TGFbRII mutations, others have shown second allele mutations in pure cultures of cell lines (Rampino et al., 1997; Markowitz et al., 1995) , but this is much more dicult to demonstrate in primary tumours due to contamination by stromal and lymphoid cells. Hence some uncertainty remains over the functional status of BAX in primary human tumours, even when there is evidence for mutation in one allele. However, we report here, we believe for the ®rst time, two patterns for such mutations. In four of the six tumours bearing BAX mutations, identical alterations in the [(G)8] tract were found in all sites sampled within each cancer, supporting the hypothesis that BAX mutation was present in the founder malignant clone. This pattern is also consistent with that described for BAX mutations in gastric cancers (Chung et al., 1997) . However, in two of six cases we demonstrated a second pattern in which BAX mutation is not shared by all the tumour sites of the same cancer. We can not completely exclude the possibility that the apparently unaltered [(G)8] tract found in subclones of these tumours represents a reversion, through a second mutation, of the [(G)8] mutation present elsewhere. This possibility can in the future be tested in appropriate cell culture models. A more obvious explanation, however, is that in these tumours the BAX [(G)8] mutation was not present in the founder malignant clone but was acquired later in cancer progression. In these tumours, it is dicult to sustain the view that mutational inactivation of BAX could have been a critical event early in carcinogenesis. These data therefore raise some doubt as to the signi®cance of loss of BAX-dependent apoptosis pathways in colorectal carcinogenesis. Rather than indicating that failure of apoptosis exerts a critical role in carcinogenesis, some BAX mutations in colorectal tumours may merely aid tumour progression, or indeed may simply re¯ect the consequences of mismatch repair de®ciency without a functional connotation. 
Materials and methods
Tissue samples
Fresh tumour samples were collected from patients with colorectal carcinoma undergoing surgery in the Royal In®rmary of Edinburgh NHS Trust. Samples were collected from the operating theatre within 30 min of resection and transported to the Pathology Department. Two to seven small tumour pieces and the matched normal tissues from each case were frozen in liquid nitrogen, then stored at 7708C. DNA was extracted from frozen tissues by the method of Goelz et al. (1985) .
RER status analysis
Sixty tumours were originally screened for microsatellite instability and only RER+ cases were analysed for BAX gene mutation. All the samples were tested at ®ve microsatellite loci including the highly unstable BAT-26 locus, claimed to be sucient alone for identifying the RER status (Zhou et al., 1998; Hoang et al., 1997) . The other 4 loci included L-myc, TGFbRII, D13S160, and D2S123 using the primers and conditions described elsewhere (Young et al., 1995; Huang et al., 1996) .
BAX gene analysis
Twelve RER+ cases with a total of 45 dierent tumour sites and the matched normal tissue constituted in the material for BAX gene mutational analysis.
A DNA segment of 94-base pairs encompassing the [(G)8] tract in BAX was ampli®ed by PCR using the primers described by Rampino et al. (1997) . PCR was carried out for 30 cycles, each consisting of denaturation for 30 s at 948C, annealing for 30 s at 558C, extension for 30 s at 728C. Reactions consisted of 50 ul volume containing 100 ng genomic DNA, 10 pmols of each primer, 200 uM of each dNTP (Advanced Biotechnologies Ltd), 1.5 mM MgCl 2 , 1.25 U of thermostable Taq DNA polymerase and buer consisting of 20 mM Tris-HCl (pH 8.4), 50 mM KCl and 0.05% non-ionic detergent (Life Technologies UK). The PCR hot start method was used. The products were analysed by electrophoresis on 2% agarose gels for detection of the ampli®ed product.
The forward primer was end labelled with g-33 P-ATP using T4 polynucleotide kinase according to the manufacturer's instructions (Life Technologies UK). This primer was then used to label the original PCR product by performing one PCR cycle using the same conditions as described above. The radio-labelled products were electrophoretically separated in denaturing 6% polyacrylamide gel and subjected to autoradiography for detection of band shifts. At the same time, all the original PCR products were directly sequenced with Thermosequenase radiolabelled terminator cycle sequencing kits (Amersham Life Science).
